For over 30 years, our team has empowered exceptional entrepreneurs through the provision of capital, expertise, and market access.
We exclusively invest in large unmet patient needs in chronic diseases, with an emphasis on cardio & neurovascular disorders, the worldwide leading causes of death and the largest cost driver in the global healthcare systems. Our mission is to improve patient outcomes and quality of life at lower long-term healthcare costs.
Investment Strategy
- Sector: Medical Technologies
- Stage: Clinical through Commercial
- Europe, Israel & North America
- €5-15 Million per Company
Sectors we invest in:
- Structural Heart Disease
- Heart Failure
- Aortic & Peripheral Vascular Disease
- Neurovascular Disease / Stroke
- Hypertension
- Electrophysiology
- Neuromodulation for Chronic Diseases (e.g. Cardiovascular, Sleep Apnea)
- Medical Imaging
- Medical Robotics
- Patient Monitoring
Sectors we do not invest in:
- Biotech/Pharma
- Healthcare Services
- Wellness Products
Value Creation
Through close collaborations with leading physicians and healthcare providers, we support entrepreneurs from R&D stage through clinical trial execution and commercialization.
Besides support with clinical, regulatory and reimbursement strategies, we leverage existing commercial partnerships to provide our portfolio companies with access to a €2bn commercial channel in Europe (Uniphar PLC & CoRRect Medical GmbH).